The companies will work together to advance the use of ApoCell's rare cell isolation platform for cancer molecular profiling and monitoring in clinical trials.
The partners said they will also combine their respective expertise to offer pharmaceutical companies help in developing companion diagnostics for oncology.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
The company said it plans to use the proceeds of the offering for general corporate purposes.
The firm said its Focus::Myeloid NGS-based panel for myeloid malignancies provides information for diagnosis, prognosis, treatment, and risk stratification of patients.
The company's revenues saw strong growth on gains in its biopharma services and clinical services operations.
Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate.
The panel targets actionable markers in seven genes to provide information related to patient stratification, disease management, and treatment selection.
The test is a microarray-based assay that analyzes the expression of 2,000 genes to identify the most likely tissue of origin for 15 common tumor types.
In Nature this week: genetic history of HIV in the US, and more.
There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.
A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.
Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.